Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2000-12-26
2003-04-01
Borin, Michael (Department: 1631)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S008100, C530S385000
Reexamination Certificate
active
06541449
ABSTRACT:
BACKGROUND OF THE INVENTION
Classically, the transfer of oxygen to tissue locations in humans and other vertebrate animals has been defined as being functionally dependent upon red blood cell (RBC) flux associated with the tissue, specifically the flow rate and hematocrit of RBCs, and upon the difference in oxygen content between arterial and venous RBCs. Further, the amount of oxygen transfer from the flow of other components of the circulatory system, such as plasma, typically has been a negligible fraction of the total oxygen delivered by the RBCs. Normally, RBCs contain about 98% of the arterial oxygen content. Thus, a condition leading to a localized, regionalized and/or systemic reduction in the circulation of RBCs, often resulting from a blood vessel constriction or occlusion, or from a reduced number of normal RBCs in the cardiovascular system, can result in local, regional or systemic tissue hypoxia, tissue death and possibly even in the death of the human or other vertebrate.
Current methods for treating many causes of tissue hypoxia, particularly hypoxia resulting from a reduction in RBC flow, are typically ineffectual and/or require long, time-consuming procedures before restoring adequate oxygen delivery to the hypoxic tissue.
Therefore, a need exists for a faster more effective method of delivering oxygen to hypoxic tissue having inadequate RBC flow.
SUMMARY OF THE INVENTION
The present invention relates to a method for increasing organ function of a vertebrate, while the organ has reduced red blood cell flow due to a least one partial obstruction of a blood vessel within the circulatory system of the vertebrate, and wherein the vertebrate has a normovolemic blood volume and at least a normal systemic vascular resistance, comprising introducing hemoglobin into the circulatory system of the vertebrate, at least one dose of hemoglobin, thereby increasing function of the organ.
This invention has many advantages, including reducing the probability and extent of organ hypoxia, and of possible tissue necrosis, resulting from at least a partial reduction in RBC flow. Another advantage is improved survivability for a vertebrate suffering from a significant reduction in RBC flow to a vital organ or portion thereof. This invention also allows the performance of invasive procedures, which require restriction of RBC flow, without significantly reducing oxygenation of distal organ tissue.
REFERENCES:
patent: 4704402 (1987-11-01), Abraham et al.
patent: 4988515 (1991-01-01), Buckberg
patent: 5084558 (1992-01-01), Rausch et al.
patent: 5296465 (1994-03-01), Rausch et al.
patent: 5296466 (1994-03-01), Kilbourn et al.
patent: 5334706 (1994-08-01), Przybelski
patent: 5854209 (1998-12-01), Jacobs, Jr. et al.
patent: 5877146 (1999-03-01), McKenzie et al.
patent: WO 95/26195 (1995-10-01), None
Biro, G. P., et al., “Early Deleterious Hemorheologic Changes Following Acute Experimental Coronary Occlusion and Salutary Antihyperviscosity Effect of Hemodilution with Stroma-Free Hemoglobin,”American Heart Journal, 103(5):870-878 (1992).
Biro, G. P. et al., “The Effect of Hemodilution with Stroma-Free Hemoglobin and Dextran on Collateral Perfusion of Ischemic Mycocardium in the Dog,”American Heart Journal, 99(1):64-75 (1980).
Cole, D. J., et al., “Focal Cerebral Ischemia in Rats: Effect of Hypervolemic Hemodilution with Diaspirin Cross-Linked Hemoglobin versus Albumin on Brain Injury and Edema,”Anesthesiology, 78(2):335-342 (1993).
Cole, D. J., et al., “Focal Cerebral Ischemia in Rats: Effect of Hemodilution with &agr;-&agr;Cross-Linked Hemoglobin on CBF,”J. Cereb. Blood Flow Metab., 12(6):971-976 (1992).
Cole, D. J., et al., “Effects of Viscosity and Oxygen Content on Cerebral Blood Flow in Ischemic and Normal Rat Brain,”Journal of Neurological Sciences, 124:15-20 (1994).
Feola, M., et al., “Clinical Trial of a Hemoglobin Based Blood Substitute in Patients with Sickle Cell Anemia,”SURGERY, Gynecology&Obstetrics, 174:379-386 (1992).
Feola, M., et al., “Improved Oxygenation of Ischemic Myocardium by Hemodilution with Stroma-Free Hemoglobin Solution,”CHEST, 75(3):369-375 (1979).
Hauser, C. J. et al., “Hemoglobin solution in the Treatment of Hemorrhagic Shock,”Critical Care Medicine, 10(4):283-287 (1982).
Homer, L. D., et al., “Oxygen Gradients Between Red Blood Cells in the Microcirculation,”Hypoxia Between Red Cells, Academic Press, Inc., 308-323 (1981).
Leone, B. J. et al, “Anemia, Hemodilution, and Oxygen Delivery,”Anesth. Analg., 75:651-653 (1992).
Sarelius, I. H., “Cell and Oxygen Flow in Arterioles Controlling Capillary Perfusion,”Am. J. Physiol., 265 (Heart Circ. Physiol.) 34:H1682-H1687 (1993).
Standl, T., et al., “Hemodynamics and Oxygen Transport During Complete Isovolemic Hemodilution with a New Ultrapurified Polymerized Bovine Hemoglobin Solution in a Dog Model.” Paper presented at the Annual Meeting of the American Society of Anesthesiologists, Washington (1993) and at the Central European Congress of Anaestheiology, Dresden (1993).
Tsai, A. G. et al. “Local Tissue Oxygenation During Constant Red Blood Cell Flux: A Discrete Source Analysis of Velociy and Hematocrit Changes,”Microvascular Research, 37:308-322 ( 1989).
Wei, E. P., et al., “Effect of Local Change in O2Saturation of Hemoglobin on Cerebral Vasodilation from Hypoxia and Hypotension,”Am. J. Physiol., 265 (Heart Circ. Physiol, ), 34: H1439-H1443 (1993).
Chu, D., et al., Abstract 80.13, “The Effect of Hemodilution with a Purified Monomer or Purified Bovine Hemoglobin on Infarct Size in Focal Ishemia in Rabbits,”Society for Neuroscience Abstract, 20:180 (1994), presented at the 24th Annual Meeting Society of Neuroscience, Miami Beach, FL (Nov. 13-18, 1994).
Hodakowski, G. T., et al., “Greater Maximal Hyocardial oxygen Delivery after Hemodilution with Polymerized Bovine Hemoglobin Blood Substitute,”Surgical Forum—Cardiothoracic Surgery, 41:304-306 (1990).
Teicher, B. A., et al., “Oxygenation of tumors by a hemoglobin solution,”J. Cancer Res Clin Oncol, 120:85-90 (1993).
Waschke, K., et al., “Local Cerebral Blood Flow and Glucose Utilization After Blood Exchange with A Hemoglobin-Based O2 Carrier in Conscious Rats,”Amer. J. Physiol., 265:H1243-H1248 (Jun. 1993).
MacDonald, Victor W. et al., “Oxygen delivery and myocardial function in rabbit hearts perfused with cell-free hemoglobin,”J. Appl. Physiol. 72(2):476-483 (1992).
Nakajima, I. et al., “Long Term Liver Preservation Using Artificial Blood Substitutes,”Biomat., Art, Cells, Art, Org., 16(1-3):347-354 (1988).
Tam, Siu-Cheung et al., “Impairment of renal function by stroma-free hemoglobin in rats,”J. Lab Clin. Med., 111:189-193 (1988).
Tanaka, Jun-ichi et al., “Does Oxygen Supply Improve Graft Viability in Liver Preservation?”Biomat., Art. Cells, and Immob. BioTech., 20(2-4):545-548 (1992).
Hodakowski. G. T., et al., “Greater maximal myocardial oxygen delivery after hemodilution with polymerized bovine hemoglobin blood substitute,” reprinted fromAmerican College of Surgeons, Forum vol. XLI:304-306 (1990).
Hodakowski, G. T., et al., “Ultra-pure polymerized bovine hemoglobin blood substitute: Effects on the coronary circulation,”Biomat., Art. Cells&Immob. Biotech., 20(204):669-672 (1992).
Horn et al., “Bovine Hemoglobin increases skeletal muscle oxygenation during 95% artificial arterial stenosis,”Surgery, 121 (4) :411-418 (1997).
Spahn et al., “Acute isovolemic hemodilution and blood transfusion,”The J. of Thoracic and Cardiovascular Surgery, 105 (4) :694-704 (1993).
Standl et al., “Bovine Hemoglobin Restores Myocardial Tissue Oxygen Tension in Dogs with Acute Critical Coronary Stenosis and Extended Hemodilution,”Anesthesiology, 91 (3A) (1999) (From Abstracts of Scientific Papers 1999 Annual Meeting, Abstract No. A697).
Jacobs, Jr. Edward E.
Rausch Carl W.
Biopure Corporation
Borin Michael
Hamilton Brook Smith & Reynolds P.C.
LandOfFree
Increasing function of organs having reduced red blood cell... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Increasing function of organs having reduced red blood cell..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Increasing function of organs having reduced red blood cell... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3098915